Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus

Simple item page
dc.contributor.authorLobigs, M.
dc.contributor.authorLarena, M.
dc.contributor.authorAlsharifi, M.
dc.contributor.authorLee, E.
dc.contributor.authorPavy, M.
dc.date.issued2009
dc.description.abstractThe Japanese encephalitis virus (JEV) serocomplex, which also includes Murray Valley encephalitis virus (MVEV), is a group of antigenically closely related, mosquito-borne flaviviruses that are responsible for severe encephalitic disease in humans. While vaccines against the prominent members of this serocomplex are available or under development, it is unlikely that they will be produced specifically against those viruses which cause less-frequent disease, such as MVEV. Here we have evaluated the cross-protective values of an inactivated JEV vaccine (JE-VAX) and a live chimeric JEV vaccine (ChimeriVax-JE) against MVEV in two mouse models of flaviviral encephalitis. We show that (i) a three-dose vaccination schedule with JE-VAX provides cross-protective immunity, albeit only partial in the more severe challenge model; (ii) a single dose of ChimeriVax-JE gives complete protection in both challenge models; (iii) the cross-protective immunity elicited with ChimeriVax-JE is durable (>5 months) and broad (also giving protection against West Nile virus); (iv) humoral and cellular immunities elicited with ChimeriVax-JE contribute to protection against lethal challenge with MVEV; (v) ChimeriVax-JE remains fully attenuated in immunodeficient mice lacking type I and type II interferon responses; and (vi) immunization with JE-VAX, but not ChimeriVax-JE, can prime heterologous infection enhancement in recipients of vaccination on a low-dose schedule, designed to mimic vaccine failure or waning of vaccine-induced immunity. Our results suggest that the live chimeric JEV vaccine will protect against other viruses belonging to the JEV serocomplex, consistent with the observation of cross-protection following live virus infections.
dc.description.statementofresponsibilityMario Lobigs, Maximilian Larena, Mohammed Alsharifi, Eva Lee and Megan Pavy
dc.identifier.citationJournal of Virology, 2009; 83(6):2436-2445
dc.identifier.doi10.1128/JVI.02273-08
dc.identifier.issn0022-538X
dc.identifier.issn1098-5514
dc.identifier.urihttp://hdl.handle.net/2440/59096
dc.language.isoen
dc.publisherAmer Soc Microbiology
dc.rightsCopyright © 2009, American Society for Microbiology. All Rights Reserved.
dc.source.urihttps://doi.org/10.1128/jvi.02273-08
dc.subjectAnimals
dc.subjectMice, Inbred C57BL
dc.subjectMice, Knockout
dc.subjectHumans
dc.subjectMice
dc.subjectEncephalitis Virus, Japanese
dc.subjectEncephalitis Virus, Murray Valley
dc.subjectEncephalitis, Arbovirus
dc.subjectVaccines, Synthetic
dc.subjectVaccines, Attenuated
dc.subjectAntibodies, Viral
dc.subjectImmunization, Secondary
dc.subjectSurvival Analysis
dc.subjectCross Reactions
dc.subjectImmunologic Memory
dc.subjectTime Factors
dc.subjectFemale
dc.subjectMale
dc.titleLive chimeric and inactivated Japanese encephalitis virus vaccines differ in their cross-protective values against Murray Valley encephalitis virus
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Molecular and Biomedical Science publications